No, increasing mirtazapine above 15 mg does NOT make it more sedating—it actually becomes LESS sedating at higher doses.
The Paradoxical Dose-Sedation Relationship
Mirtazapine exhibits an inverse relationship between dose and sedation: lower doses (7.5-15 mg) produce MORE sedation than higher doses (30-45 mg). This counterintuitive pharmacology stems from its receptor binding profile at different concentrations 1.
Mechanism Behind the Paradox
At lower doses (15 mg and below):
- Predominantly blocks histamine H1 receptors, which are primarily responsible for sedation 1
- Minimal noradrenergic activity
- Maximum sedative effect occurs
At higher doses (30-45 mg):
- Increased antagonism of α2-adrenergic autoreceptors and heteroreceptors
- Enhanced noradrenergic activity that counteracts histamine-mediated sedation 1
- Net result: reduced sedation despite higher drug levels
Clinical Evidence
Research directly addressing this question 2 demonstrated that patients on 30 mg mirtazapine reported earlier sleep onset and longer sleep duration initially, but daytime alertness actually IMPROVED progressively during treatment, reaching levels 18% higher than baseline by week 2. Importantly, somnolence was reported by only 10% of patients during the first week and decreased thereafter.
A driving performance study 3 confirmed this pattern:
- 7.5 mg mirtazapine: No significant driving impairment
- 15 mg mirtazapine: Impaired road-tracking performance
- Dose increase from 7.5 to 15 mg showed no additional detrimental effects
Practical Clinical Implications
If sedation is problematic at 15 mg:
- Increase to 30 mg rather than decreasing dose 4
- The 15→30 mg increase showed significantly greater symptom improvement (p=0.003) in early non-responders
- Sedative effects are typically temporary and resolve within 1-2 weeks 5
If sedation is desired (e.g., for insomnia):
- Use 7.5-15 mg doses 6
- Guidelines specifically recommend mirtazapine as a sedating antidepressant for refractory insomnia, particularly effective in patients with comorbid depression and anorexia 6
Important Caveats
- Individual pharmacokinetic variability exists: women show 18% higher concentration-to-dose ratios, and elderly patients demonstrate 27% higher ratios 7
- Plasma concentrations below 30 ng/mL correlate with non-response 5
- The FDA label confirms that sedation is explained by H1 receptor antagonism, not dose-dependent enhancement 1
Bottom line: If your patient complains of excessive sedation on 15 mg, increasing to 30 mg will likely reduce—not worsen—daytime sedation while improving antidepressant efficacy. The sedation at lower doses is a pharmacological quirk, not a dose-dependent effect.